Serum thymidine kinase activity as a "real-time" clinical biomarker of tumor response to CDK4/6 inhibition in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer

被引：0
|
作者：
Bagegni, Nusayba
Williams, Amy
Grigsby, Isabella
Bergqvist, Mattias
Clifton, Katherine
Ma, Cynthia
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-15-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-15-06
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [2] TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity
    Bagegni, Nusayba A.
    Grigsby, Isabella
    Nehring, Leslie
    Luo, Jingqin
    Carson, Jennifer Powers
    Gibson, David W.
    Horvath, Meghan
    Clifton, Katherine K.
    Ademuyiwa, Foluso O.
    Suresh, Rama
    Frith, Ashley
    Davis, Andrew A.
    Peterson, Lindsay L.
    Bose, Ron
    Williams, Amy
    Bergqvist, Mattias
    Ma, Cynthia
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [4] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [5] SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR+)/HER2-breast cancer
    Van Geelen, Courtney T.
    Teo, Zhi Ling
    Savas, Peter
    Luen, Stephen J.
    Clarke, Kylie A.
    Sant, Sneha
    Cowley, Karla J.
    Caramia, Franco
    Simpson, Kaylene J.
    Andre, Fabrice
    Dawson, Sarah-Jane
    Pearson, Richard
    Loi, Sherene
    CANCER RESEARCH, 2023, 83 (05)
  • [6] COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) EARLY BREAST CANCER
    Tejerina-Peces, Julia
    Amann-Arevalo, Marta
    Ballestin, Pablo
    Gonzalez-Diez, Beatriz
    Paz-Cabezas, Mateo
    Pascual, Alejandro
    de Luna, Alicia
    Garcia-Barberan, Vanesa
    Lopez de Sa, Alfonso
    Garcia-Saenz, Jose Angel
    Moreno, Fernando
    CANCER RESEARCH, 2024, 84 (09)
  • [7] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [8] Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
    Migliaccio, Ilenia
    Leo, Angela
    Galardi, Francesca
    Guarducci, Cristina
    Fusco, Giulio Maria
    Benelli, Matteo
    Di Leo, Angelo
    Biganzoli, Laura
    Malorni, Luca
    CANCERS, 2021, 13 (11)
  • [9] The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
12345